Neovasc Chosen as Finalist for the Fierce Innovation Awards
Neovasc has been selected as a finalist in this year’s Fierce Innovation Awards – LifeSciences Edition, for the Reducer product. The Fierce Innovation Awards is a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma and highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies.
Finalists’ applications were reviewed by an exclusive panel of executives from major biotech and pharma companies and were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.
An effective percutaneous treatment for refractory angina, a severely debilitating condition that affects millions globally.
Treats a large and growing population of patients suffering from refractory angina who have limited options
Currently CE Marked
COSIRA data showed patients treated with Reducer were 2.3 times more likely to see an improvement of two Canadian Cardiovascular Society (CCS) functional classification as compared to the control arm (n = 104, p value = 0.024).
Note: The CCS class is a functional classification used to stratify the severity of angina by evaluating angina symptoms with activity levels. N Eng J Med 2015;372:519-527
How the Reducer Works
A Reducer Success Story
The Reducer has been added to the European Society of Cardiology Practice Guidelines at the highest recommendation class for therapies addressing refractory angina. learn more >
Positive results from the COSIRA clinical trial. here >
A library of publications about the ReducerTMhere >
This device is currently only available in the EU.
For more information on Reducer for all European countries outside of Germany, kindly message Mark Niggli, VP European Sales and Marketing, here >
For more information on Reducer specific to Germany, kindly contact Andreas Mayer, Senior Director DACH, here >